OCA, a semi-synthetic bile acid was formerly approved in treating primary biliary cholangitis (PBC) and induces the activation of the nuclear bile acid receptor farnesoid X receptor (FXR) which in turn results in attenuation of bile acids. This evidence concerns the gene NR1H4 and biliary liver cirrhosis.